Oncoclínicas do Brasil Serviços Médicos (ONCO3) clarified, in a statement dated Friday, August 28, 2026, points of its out-of-court recovery plan related to the restructuring of unsecured financial debt in the approximate amount of R$ 5.1 billion, as well as other intercompany credits. The company notes that the request for out-of-court recovery was filed on July 13, 2026 and that the proceeding was accepted on August 4, 2026 by the Court of the 3rd Bankruptcy and Judicial Reorganization Court of São Paulo.
In the statement, Oncoclínicas reports that on August 26, 2026, it filed an updated draft of the Out-of-Court Recovery Plan, reflecting the restructuring terms and mechanisms negotiated so far with the covered creditors. The company points out that it has already published three material facts on the subject: filing of the initial petition, acceptance of the proceeding, and filing of the updated draft of the plan, which is not yet final.
The company highlights differences between the draft plan and a news article published by Valor newspaper on August 26, 2026. According to Oncoclínicas, the article described, for Payment Option B, settlement of 20% of the debt in 15 annual installments adjusted by the IPCA inflation index, whereas clause 6.3.3 of the plan provides for payment of principal in a single installment on the 15th anniversary of the debentures’ issue date. The company also states that the plan offers four payment methods (Option A, Option B, Supporter Modality 1 and Supporter Modality 2), and not three, as mentioned in the article.
Regarding the supporter creditor modalities, Oncoclínicas clarifies that eligibility requires the creditor to maintain or resume a commercial relationship for the supply of goods or services with the company, which makes this route unavailable to purely financial creditors. The company adds that the R$ 9 million cap, with irrevocable waiver of any excess amount, applies specifically to Supporter Modality 2 creditors, a point that was allegedly not detailed in the article.
Oncoclínicas emphasizes that negotiations to define the final conditions of the Out-of-Court Recovery Plan remain ongoing during the period set forth in article 163, paragraph 7, of Law 11,101/2005, and that the plan may be amended until the end of the legal 90-day period. The company reiterates its commitment to keep the market informed whenever there are material facts related to the out-of-court recovery process.
